TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over year. See the Zacks Earnings Calendar to stay ahead of market-making news.
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...
Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...
BofA Securities made adjustments to its financial model for Teva Pharmaceutical Industries Ltd (NYSE:TEVA), resulting in a lowered price target. While the firm maintained a Buy rating on the stock, ...
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss. Shares fell about 2.5% in premarket trading to $20.99.
UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback